Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Online cash loans - online payday loans, fast cash.
Popular Articles
Stretch Mark Remedies

Today's Selection Of Opinions And Editorials
Reform Needs Healthy Life Incentives The Wall Street Journal
generic viagra online
APhA Publishes New Print, CD-ROM Editions Of Handbook Of Pharmaceutical Excipients
The American Pharmacists Association (APhA) will publish this month the sixth edition of Handbook of Pharmaceutical Excipients and the corresponding single-user CD ROM, titled Pharmaceutical Excipients 6.
News of the day
Shanghai To Relax One-Child Policy As China Faces Aging Population, Shrinking Work Force
Nearly three decades after China implemented its one-child policy, the city of Shanghai is planning to encourage young couples to have a second child in an effort to address the country"s aging population and shrinking work force, the New York Times reports. The city"s plan is the most public effort made by the government to counteract a program that is "considered both a tremendous success and a terrible failure," the Times reports. The policy has managed to keep population growth under control but also has led to forced abortions, according to the Times.The country is not abandoning the one-child policy, which applies mostly to residents in urban areas. Rather, the government is allowing more exceptions to the rule, with Shanghai -- where about 22% of its 20 million residents are older than age 60 -- leading the effort. China as a whole faces a similar problem seen in Shanghai, the Times reports. About 8% of the country"s population was older than age 65 in 2006. That figure is expected to increase threefold by 2050 to about 322 million people, or nearly 25% of the population, according to the United Nations.In Friday"s issue of China Daily, Xie Lingli, director of the Shanghai Population and Family Planning Commission, was quoted as saying, "We advocate eligible couples to have two kids because it can help reduce the proportion of the aging people and alleviate a work force shortage in the future." City officials plan to visit homes, pass out leaflets, and offer counseling and financial incentives, the Times reports. Current exceptions to the one-child policy are in place for ethnic minorities and rural residents, who can have a second child if the first child is a girl. Couples made up of two parents who have no siblings have always been allowed to have a second child and are now being encouraged to do so (Barboza, New York Times, 7/24).
Cardiovascular

NeurogesX Announces New PDUFA Date For Qutenza(TM) New Drug Application

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date from August 16, 2009 to November 16, 2009 to review the new drug application (NDA) for Qutenza(TM) to manage pain associated with postherpetic neuralgia (PHN). The extension resulted from the Company"s recent submission of data requested by the agency late in the review cycle, which the FDA has classified as a major NDA amendment. Submission of a major amendment within three months of the PDUFA date can trigger a three-month extension to the original review timeline. Anthony DiTonno, President and CEO, commented, "The FDA"s three-month extension is not unexpected. We previously discussed the potential for this extension as a result of our responses to FDA requests for additional information. The information we submitted in July included the report from our recently completed C123 Study, which was performed at the request of the FDA. We believe that with this updated review timeline, if we gain approval in November, we may still achieve our overall goal of launching Qutenza in the United States in the first half of 2010." About NeurogesX, Inc. NeurogesX (NASDAQ: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX" late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009. NeurogesX" second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the design and timing of further development efforts. NeurogesX" early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs. Safe Harbor Statement This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; acceptance of clinical trial or other data, analysis or information by the FDA in support of regulatory approval; plans and timing for commercialization of Qutenza; outcomes and interpretation of the results of clinical trials; and plans for entry into a U.S. commercialization partnership, including the timing with respect to entry into such a partnership. Such statements are based on management"s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX" product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX" product candidates. For further information regarding these and other risks related to NeurogesX" business, investors should consult NeurogesX" filings with the Securities and Exchange Commission. NeurogesX, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009